TrialBreast cancer research : BCR2020
A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer.
Lori J Goldstein et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
72 papers cite itlatest 60 shown
this paperpooled ittrialcites it